Vizamyl

Handle VIZAMYL with appropriate safety measures to minimize radiation exposure during administration [see Warnings and Precautions (5.3)]. Use waterproof gloves and effective radiation shielding, including lead-glass syringe shields when handling and administering VIZAMYL.

Radiopharmaceuticals, including VIZAMYL, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

• Position the patient supine with the head positioned to center the brain, including the cerebellum, within a single field of view. The patient's head should be tilted so that the anterior commissure-posterior commissure (AC-PC) plane is at right angles to the bore-axis of the PET scanner, with the head positioned in a suitable head support. Tape or other flexible head restraints may be employed to reduce head movement.
• Acquire 10-minute to 20-minute PET images starting 60 minutes to 120 minutes after VIZAMYL administration using a PET scanner in 3-D mode with appropriate data corrections.
• Iterative or filtered back-projection reconstruction is recommended with a slice thickness of 2 mm to 4 mm, and matrix size of 128 × 128 with pixel sizes of approximately 2 mm. Where a post-smoothing filter is applied, full width at half maximum (FWHM) of not more than 5 mm is recommended; filter FWHM should be chosen to optimize the signal-to-noise ratio while preserving the sharpness of the reconstructed image.

Estimated radiation absorbed doses for adults following intravenous injection of VIZAMYL are shown in Table 1.

Values were calculated from human biodistribution data using OLINDA/EXM software and assuming emptying of the urinary bladder at 3.5-hour intervals.

The whole-body effective dose resulting from administration of 185 MBq (5 mCi) of VIZAMYL to an adult is estimated to be 5.9 mSv. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition.

Serious hypersensitivity reactions including anaphylaxis, presenting with flushing, dyspnea, and hypotension, have been observed within minutes following VIZAMYL administration. These reactions may occur in patients with no history of exposure to VIZAMYL [see Adverse Reactions (6.1, 6.2)].

Obtain a history of allergy or hypersensitivity reactions. Always have resuscitation equipment and trained personnel immediately available at the time of VIZAMYL administration. If a hypersensitivity reaction is suspected, immediately discontinue the injection and initiate appropriate therapy. VIZAMYL is contraindicated in patients with a history of hypersensitivity to VIZAMYL or polysorbate 80 [see Contraindications (4)].

Errors may occur in the estimation of amyloid beta neuritic plaque density during VIZAMYL image interpretation [see Clinical Studies (14)].

The use of clinical information in the interpretation of VIZAMYL images has not been evaluated and may lead to an inaccurate assessment. Extensive brain atrophy and motion artifacts that distort the image may limit the ability to distinguish gray and white matter on a VIZAMYL scan.

Perform image interpretation independently of the patient's clinical information. For cases where there is uncertainty as to the location of cortical signal, use co-registered anatomical imaging to improve localization of signal or examine the striatum for VIZAMYL signal as it is less affected by atrophy [see Dosage and Administration (2.5)].

VIZAMYL contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration (2.1 , 2.2)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of VIZAMYL was evaluated in 761 adult subjects who received VIZAMYL by intravenous injection in clinical trials. Most subjects (70%) received a dose of 185 MBq (5 mCi). The subjects had a mean age of 62 years (range 18 years to 93 years); 45% of the subjects were male and 91% were White.

A serious hypersensitivity reaction characterized by flushing, dyspnea, and chest pressure was reported within minutes following VIZAMYL administration in one subject who recovered with treatment.

Adverse reactions reported in ≥ 1% of subjects from the clinical trials are shown in Table 2.

The following adverse reactions have been identified during postapproval use of VIZAMYL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The safety and effectiveness of VIZAMYL have not been established in pediatric patients.

Of the 761 subjects in clinical studies of VIZAMYL, 447 (59%) subjects were 65 years of age and older, while 246 (32%) subjects were 75 years of age and older. No overall differences in safety or effectiveness were observed between subjects 65 years of age and older and younger adult subjects.

VIZAMYL (flutemetamol F 18 injection) is a radioactive diagnostic drug for intravenous use.

Chemically, flutemetamol F 18 is 2-[3-[¹⁸F]fluoro-4-(methylamino) phenyl]-6-benzothiazolol. It has the molecular formula C₁₄H₁₁ ¹⁸FN₂OS, the molecular weight 273.32, and the following structural formula:

VIZAMYL is a sterile, non-pyrogenic, clear, colorless to slightly yellow solution. Each mL contains up to 2 mcg of flutemetamol and 150 MBq (4.05 mCi) of flutemetamol F 18 at reference date and time with the following inactive ingredients: 70 microL ethanol, 9 mg sodium chloride, and 4.98 mg polysorbate 80 (w/v) in 0.014 M aqueous phosphate buffer. The pH of the solution is between 6 and 8.5.

Fluorine-18 (F 18) decays by positron emission (ß+ decay, 96.7%) and orbital electron capture (3.3%) to stable oxygen-18 and has a physical half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3).

The point source air-kerma rate constant for F 18 is 3.74E -17 Gy m²/(Bq s); this coefficient was formerly defined as the specific gamma-ray constant of 5.7 R/hr/mCi at 1 cm. The first half-value thickness of lead (Pb) for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in Table 4. The use of ~8 cm of Pb will decrease the radiation transmission (i.e., exposure) by a factor of about 10,000.

For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 5.

Flutemetamol F 18 binds to amyloid beta plaques in the brain and the F 18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing fibrillar amyloid beta, the dissociation constant (Kd) for flutemetamol was 6.7 nM.

Selectivity of ³H-flutemetamol binding in postmortem human brain sections was demonstrated using autoradiography, silver-stained protein, and immunohistochemistry (monoclonal antibody to amyloid beta) correlation studies.

Following intravenous injection, flutemetamol F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain flutemetamol F 18 content, with differential retention of the drug in cortical areas that contain amyloid beta aggregates compared to areas that lack the aggregates. The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection. Differences in signal intensity between brain regions showing specific and non-specific flutemetamol F 18 uptake form the basis for the image interpretation method [see Dosage and Administration (2.5)].

The test-retest distribution of flutemetamol F 18 was evaluated in five subjects with probable AD who underwent two administrations of flutemetamol F 18 (followed by PET scans) separated by a time period of 1 to 4 weeks. Images were shown to maintain signal distribution reproducibility when evaluated semi-quantitatively using an automated assessment of SUVR in pre-specified cortical regions.

Following intravenous administration of 185 MBq (5 mCi) of VIZAMYL in healthy subjects, flutemetamol F 18 plasma concentrations declined by approximately 75% in the first 20 minutes post-injection, and by approximately 90% in the first 180 minutes. The F 18 in circulation during the 30-minute to 120-minute imaging window was principally in the form of flutemetamol metabolites. Excretion was approximately 37% renal (28% to 45%; n=6) and 52% hepatobiliary (40% to 65%; n=6).

Animal studies have not been performed to evaluate the carcinogenicity or reproductive toxicity potential of flutemetamol F 18.

The effectiveness of VIZAMYL was evaluated in two single-arm clinical studies (i.e., Studies 1 and 2) in adult subjects with a range of cognitive function, including some terminally ill subjects who had agreed to participate in a postmortem brain donation program as well as healthy subjects. Subjects underwent a VIZAMYL injection and scan. The images were interpreted using a clinically applicable binary image interpretation method (negative or positive) by five independent readers blinded to all clinical information [see Dosage and Administration (2.3, 2.4, 2.5)]. PET images were reviewed first without, and subsequently with, brain CT or MRI images. Before image interpretation, all readers underwent in-person training or electronic media training.

To determine the agreement between the in vivo VIZAMYL image results and the postmortem amyloid beta neuritic plaque density, VIZAMYL results (negative or positive) were pre-specified to correspond with specific histopathology-derived plaque density scores, based upon a modification of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria (Table 6), which use neuritic plaque counts as a necessary pathological feature of AD. Plaques were counted on microscope slides with modified Bielschowsky silver stained tissue sections. The global neuritic plaque density score for each subject was determined by averaging across the scores (0-3) for five gray matter fields per slide and then across six slides for each of eight regions; if any one region had a score of greater than 1.5, the subject was classified as positive for amyloid beta.

Study 1 evaluated performance characteristics (sensitivity and specificity) in terminally ill subjects by comparing the premortem VIZAMYL PET images to a postmortem truth standard of cortical amyloid beta neuritic plaque density. A total of 180 subjects were dosed with VIZAMYL and 176 were imaged. The mean age was 80 years (range 47 to 98 years) and 57% of the subjects were female. By medical history, 135 subjects had dementia, one subject had memory loss of unspecified nature, and 44 subjects had no cognitive impairment. Among the imaged subjects, 68 subjects who died during the study and had cerebral cortical amyloid status determined were included in the primary analysis. The time interval between the VIZAMYL scan and death ranged from 0 to 13 months, with a median of 2.6 months, and was less than one year for 66 subjects and between 12 to 13 months for 2 subjects. At autopsy, the global brain neuritic plaque density category (CERAD score as in Table 6) was available for 67/68 subjects: frequent (n = 19); moderate (n = 22); sparse (n = 14); and none (n = 12).

Study 2 evaluated inter-reader and intra-reader reproducibility of image interpretation using images from subjects with a truth standard (68 subjects who underwent an autopsy in Study 1 and 36 subjects who had known or suspected normal pressure hydrocephalus with in vivo brain biopsy) and subjects without a truth standard (80 subjects with amnestic mild cognitive impairment (aMCI), 33 subjects with probable AD (pAD), 28 cognitively normal subjects 55 years of age and older, and 31 young healthy subjects). Additionally, intra-reader reproducibility was assessed with images from 29 subjects (10%). Among the 276 subjects, the mean age was 68 years (range 20 to 95 years), 136 were females, and 251 were White. Readers were naïve to all forms of amyloid PET imaging and underwent electronic media training.

Among subjects who underwent autopsy (n=68; 43 positive and 25 negative based on histopathology), the sensitivity using the majority interpretation of the readers trained using electronic media was 93% (95% CI: 81%, 99%) and specificity was 84% (95% CI: 64%, 96%). The median (and range) of correct, false negative, and false positive reads were 59 (51, 61), 5 (3, 8), 3 (2, 14), respectively, for in-person training; and were 60 (55 to 61), 3 (3 to 6), 4 (2 to 10), respectively, for electronic media training.

Table 7 shows inter-reader reproducibility results among readers for various subject groups in Study 2. Inter-reader reproducibility analyses showed an overall Fleiss' kappa statistic of 0.83 (95% CI: 0.79, 0.86), which met the pre-specified success criterion (95% CI lower bound > 0.60). Intra-reader reproducibility analyses showed that between the two readings for each of the 29 duplicate scans, one of the five readers had complete agreement for all 29 scans, two readers had discordant reads for a single scan, and two readers had discordant reads for two scans. Intra-reader reproducibility for a subgroup of eight scans from aMCI subjects showed that all five readers had complete agreement for all duplicate scans.

Refer to the prescribing information of the amyloid beta-directed therapy for description of clinical trials in which the efficacy of amyloid beta PET for selecting patients has been established.

Brain amyloid beta PET scans have been used to assess reduction of plaque in some clinical trials of amyloid beta-directed therapies as also described in the prescribing information of the therapeutic products.

How Supplied

VIZAMYL (flutemetamol F 18 injection) is a clear, colorless to slightly yellow solution supplied at a concentration of 150 MBq/mL (4.05 mCi/mL) of flutemetamol F 18 in up to 30 mL volume at reference date and time in a shielded multiple-dose glass vial (NDC 17156-067-30).

Storage and Handling

Store VIZAMYL in the original container within radiation shielding at 2°C to 30°C (36°F to 86°F).

VIZAMYL does not contain a preservative.

Do not use after the expiry date and time stated on the label. VIZAMYL multiple-dose vial expires 10 hours after end of synthesis (EOS).

Dispose of any unused product in accordance with all federal, state, and local laws and institutional requirements.

This preparation is for use by persons licensed by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

Anaphylaxis and Other Serious Hypersensitivity Reactions

Inform patients of the risk of hypersensitivity reactions, including anaphylaxis, and instruct them to alert healthcare providers immediately if they experience signs and symptoms of a hypersensitivity reaction [see Warnings and Precautions (5.1)].

Radiation Risk

Advise patients of the radiation risk of VIZAMYL. Instruct patients to increase their level of hydration before and after receiving VIZAMYL and to void frequently following administration [see Warnings and Precautions (5.3)].

Pregnancy

Inform pregnant women of the potential risks of fetal exposure to radiation doses with VIZAMYL [see Use in Specific Populations (8.1)].

Lactation

Advise a lactating woman to temporarily discontinue breastfeeding and to pump and discard breast milk for 24 hours after VIZAMYL administration to minimize radiation exposure to the breastfed infant [see Use in Specific Populations (8.2)].